Biocon Biologics has secured FDA approval for its denosumab biosimilars, Bosaya™ and Aukelso™, referencing Prolia® and Xgeva® respectively. These approvals mark a significant step in expanding access to critical biologic therapies, offering more affordable treatment options for osteoporosis and expanding the company’s oncology portfolio. The FDA also granted provisional interchangeability designation for both biosimilars.

Denosumab Biosimilars Approved

Biocon Biologics Ltd. (BBL) announced that the U.S. Food and Drug Administration (FDA) has approved Bosaya™ (denosumab-kyqq) 60 mg/mL injection and Aukelso™ (denosumab-kyqq) 120 mg/1.7 mL injection. These biosimilars reference Prolia® and Xgeva® respectively, and are indicated for subcutaneous use. The FDA granted provisional interchangeability designation for both BOSAYA and AUKELSO.

Management Commentary

Shreehas Tambe, CEO & Managing Director of Biocon Biologics, stated that these approvals represent a significant milestone in expanding access to critical biologic therapies, offering an affordable option for osteoporosis patients with Bosaya™, and further expanding their oncology care portfolio with Aukelso™.

Indications and Usage

BOSAYA is approved for treating postmenopausal women and men with osteoporosis at high risk for fracture, glucocorticoid-induced osteoporosis, increasing bone mass in men receiving androgen deprivation therapy, and women receiving adjuvant aromatase inhibitor therapy.

AUKELSO is approved for preventing skeletal-related events in patients with multiple myeloma and bone metastases from solid tumors, treating adults and skeletally mature adolescents with giant cell tumor of bone, and treating hypercalcemia of malignancy.

Clinical Data and Safety

Clinical data demonstrated comparable quality, safety, and efficacy to the reference products. BOSAYA is approved with the same Risk Evaluation and Mitigation Strategy (REMS) plan as PROLIA to inform healthcare providers and patients about the risks of severe hypocalcemia in patients with advanced chronic kidney disease.

Market Overview

As of December 2024, denosumab had nearly $5 billion in U.S. sales, with PROLIA achieving $3.3 billion and XGEVA generating $1.6 billion, according to IQVIA National Sales Perspectives Data.

Source: BSE

Neuland Laboratories has issued a corrigendum to its Postal Ballot Notice, originally dated July 31, 2025. The correction pertains to the end date of Dr. Ravi Shankar Gopinath’s term as an Independent Director. The corrected notice clarifies that his term ends on July 31, 2030, not July 31, 2025, as previously stated. The corrected notice is available on the company’s website and has been sent to shareholders electronically.

Postal Ballot Notice Amendment

Neuland Laboratories has released a corrigendum addressing a typographical error in the initial Postal Ballot Notice. The original notice, dated July 31, 2025, contained an inaccuracy regarding the term of appointment for Dr. Ravi Shankar Gopinath.

Term End Date Clarification

The corrigendum specifically addresses the end date of Dr. Gopinath’s five-year term as an Independent Director. The initial notice incorrectly stated the end date as July 31, 2025. The correct end date, as clarified in the corrigendum, is July 31, 2030. This correction ensures the accuracy and transparency of company records.

Availability of Corrected Notice

The amended Postal Ballot Notice is accessible on Neuland Laboratories’ official website. Furthermore, it has been distributed electronically to shareholders whose email addresses are registered with the company as of the cutoff date, August 22, 2025. The corrected notice ensures that all members have the proper details before voting.

Resolution Details

The postal ballot seeks shareholder approval for the appointment of Dr. Ravi Shankar Gopinath as an Independent Director for a term of five consecutive years starting from August 1, 2025. Dr. Gopinath’s appointment is further detailed in the explanatory statement, which covers his qualifications and experience.

Voting Information

The e-voting period starts on Thursday, August 28, 2025, at 9:00 AM IST and concludes on Friday, September 26, 2025, at 5:00 PM IST. Members are encouraged to carefully review the updated postal ballot notice and cast their votes electronically during this specified period.

Source: BSE

Yanmar Coromandel Agrisolutions Private Limited, a member of the promoter group of Cholamandalam Financial Holdings, has requested reclassification from the ‘promoter group’ to the ‘public’ category. As of September 16, 2025, the company held Nil paid-up equity shares and had Nil shareholding. The re-classification is subject to board and exchange approvals.

Promoter Reclassification Request

Cholamandalam Financial Holdings has received a request for reclassification from one of its promoters. Yanmar Coromandel Agrisolutions Private Limited, a member of the Company’s promoter group, seeks to change its classification to the ‘public’ category.

Shareholding Details

As of the date of the request, September 16, 2025, Yanmar Coromandel Agrisolutions Private Limited holds Nil paid-up equity shares in the company, representing Nil shareholding.

Next Steps

The requested reclassification is subject to the approval of the Board of Directors and the National Stock Exchange of India Limited and BSE Limited. The company has confirmed it will take the necessary steps to facilitate this process.

Source: BSE

JK Tyre & Industries has received a rectification order dated September 16, 2025, regarding penalties under the Central Goods and Services Tax (GST) Act. The order revises the initial penalties across multiple states. The company plans to contest the remaining penalty, believing it has a strong defense against the levy. The penalties relate to an industry-wide interpretational issue.

Rectification Order Received

JK Tyre & Industries received an order on September 16, 2025, from the Additional Commissioner, Chennai South Commissionerate. This order rectifies a previous order (dated September 3, 2025) regarding penalties under Section 73(9) of the Central Goods and Services Tax Act, 2017.

Impact of the Order

The rectification order involves penalties related to Integrated GST (IGST), Central GST (CGST), and State GST (SGST) across various states. The penalties are limited to 10% of the tax amounts involved. Here is a summary:

Lower Penalty Amounts:
The rectification order has resulted in a lower penalty across the 27 states involved.

Examples of Penalties:

• Tripura: ₹0.12 Lacs
• Goa: ₹0.57 Lacs
• Meghalaya: ₹1.02 Lacs
• Rajasthan: ₹120.55 Lacs
• Tamil Nadu: ₹157.51 Lacs
• Karnataka: ₹161.91 Lacs

Company’s Response

The company intends to contest the penalty based on Section 107 of the Central Goods and Services Tax Act, 2017. JK Tyre believes it has a strong case, aligning with the industry-wide interpretation of the issue. The company plans to file an appeal with the appropriate appellate authority to challenge the penalty.

Applicable Period

These penalties are applicable for the financial years 2017-18 and 2018-19.

Source: BSE

Anant Raj Limited will be meeting with Analyst/Institutional Investors. The meeting, organized by Nomura Financial Advisory & Securities (India) Private Limited, is scheduled for Thursday, September 25, 2025, and Friday, September 26, 2025. The meetings will be held in person in Tokyo, Japan and will be in a group or one-on-one format. This engagement aims to provide investors with an update on the company’s performance and strategic direction.

Upcoming Investor Engagement

Anant Raj Limited has announced an upcoming meeting with analysts and institutional investors. This event is intended to provide insights into the company’s operations and outlook. The meeting is organized by Nomura Financial Advisory & Securities (India) Private Limited.

Meeting Details

The investor meeting is scheduled over two days:

• Thursday, 25th September, 2025
• Friday, 26th September, 2025

The venue for the meeting is Tokyo, Japan. The meetings will be conducted in person. The format of the meetings will be either group sessions or one-on-one discussions.

Source: BSE

Yanmar Coromandel Agrisolutions (YCAS) has requested reclassification from the ‘promoter group’ to the ‘public’ category. This request follows a change in shareholding of Coromandel International Limited (CIL) in YCAS. As of September 17, 2025, YCAS holds 0.00% of equity shares in CG Power. The request is under review by CG Power’s board of directors.

Reclassification Request Overview

Yanmar Coromandel Agrisolutions Private Limited (YCAS) has formally requested to be reclassified from the ‘promoter group’ to the ‘public’ shareholder category within CG Power. The company’s board will review the request.

Background of the Request

The reclassification request is driven by a change in the shareholding structure of Coromandel International Limited (CIL) within YCAS. CIL’s stake in YCAS decreased from 40% to 10.60% due to a fund infusion of Rs.149.72 Crores by Yanmar Asia (Singapore) Corporation Pte. Ltd. on September 27, 2024. Consequently, YCAS no longer meets the definition of a ‘Promoter group’ as specified by regulations, leading to this reclassification request.

Shareholding Details

As of the date of the reclassification request (September 17, 2025), Yanmar Coromandel Agrisolutions Private Limited holds 0 equity shares in CG Power, representing 0.00% shareholding.

Next Steps

CG Power will present Yanmar’s request to its Board of Directors for review and approval. Following the board’s decision, CG Power will seek a ‘no-objection’ certificate from the National Stock Exchange of India Limited and BSE Limited.

Source: BSE

ICICI Lombard General Insurance Company Limited held analyst and institutional investor meetings on September 16, 2025. The company confirms that no presentations were made and no unpublished price-sensitive information was disclosed during the meetings. This disclosure is also available on the company’s website.

Analyst and Investor Meetings

ICICI Lombard General Insurance Company Limited successfully conducted meetings with analysts and institutional investors on September 16, 2025.

Key Discussion Points

During these meetings, no presentations were delivered, and no unpublished price-sensitive information was shared.

Participating Firms

The following firms participated in the meetings:

• DT Investment Management IFSC LLP
• Marval Capital
• WFM Asia
• India Capital Management
• Jefferies
• Seafarer Capital Partners
• Tara Capital Partners India
• AR Capital
• Chanakya Wealth Creation
• Makrana Capital Management
• ValueQuest Investment Advisors
• Beas Capital
• C&S Investment Managers
• Morgan Stanley Investment Management (MSIM)
• Norges Bank

Meeting Format

The meetings took place in Gurgaon, with DT Investment Management IFSC LLP and Marval Capital participating in one-on-one discussions. All other firms participated in a group session.

Meeting Schedule

The one-on-one meetings and group session with the analysts and investors began at 10:00 AM IST and concluded at 4:50 PM IST.

Source: BSE

PCBL Chemical has successfully completed the redemption of its Commercial Paper (CP) amounting to Rs 100 Crores. The redemption was executed on 17/09/2025, in accordance with the terms and conditions of the issuance. This announcement confirms that the company has fulfilled its payment obligations to the holders of the mentioned commercial paper. The record date for this transaction was 10/09/2025.

Redemption of Commercial Paper

PCBL Chemical announces the successful redemption of its Commercial Paper (CP) amounting to Rs 100 Crores. The company confirms that the redemption was completed on 17/09/2025, as per the terms of issuance. This demonstrates the company’s commitment to fulfilling its financial obligations.

Details of the Redemption

The following table details the specifics of the commercial paper redemption:

The record date for determining the holders of the Commercial Paper was 10/09/2025. The details above ensure transparency regarding this financial transaction.

Source: BSE

Life Insurance Corporation of India (LIC) has announced the re-designation of Jaideep Chaudhuri from Vice Principal to Principal at the Zonal Training Centre in Jamshedpur, effective September 17, 2025. This change qualifies Mr. Chaudhuri as a Senior Management Personnel (SMP) within the Corporation. He has been with LIC since 1988, holding various administrative and marketing roles.

Leadership Change at Jamshedpur Training Centre

Jaideep Chaudhuri has been re-designated as Principal, Zonal Training Centre, Jamshedpur, effective September 17, 2025. Previously, he served as the Vice Principal at the same location. This appointment places him within the Senior Management Personnel (SMP) of Life Insurance Corporation of India.

Jaideep Chaudhuri’s Background

Mr. Chaudhuri joined the Life Insurance Corporation of India in 1988 as an Assistant Administrative Officer. He holds a degree in Arts. Throughout his career spanning over three decades, he has held diverse positions in administrative and marketing roles across various offices, including the Western, East Central, and Eastern Zones, as well as the Central Office. He has also served as a Faculty Member at the Zonal Training Centres in Kolkata and Jamshedpur.

Career Trajectory

Prior to his appointment as Principal, Zonal Training Centre, Jamshedpur, Mr. Chaudhuri held the position of Vice Principal at the same institution. The change is effective as of September 17, 2025.

Source: BSE